Abstract
Over the years, the technology for producing human rabies vaccines has undergone many improvements. These improvements consist in the use of tissue cultures for the production of viral antigens, replacing the former nervous tissue substrate vaccines. The low virus yields in tissue cultures led to the development of the concentration and purification of virus supernatants. Another technical improvement was obtained by using microcarriers for virus production in VERO cell suspension cultures. This technique permits commercial-scale production of rabies vaccine, lowering production costs and thus extending the availability of the vaccine to a broader population in developing countries.
Besides improvements in rabies vaccine production technology, the use of various vaccination regimens and routes of administration in field trials has resulted in considerable gains in our experience of postexposure treatment (PET) of this disease. The standard WHO recommended regimen for PET using concentrated and purified tissue culture vaccines consists of a 5-dose course of intramuscular injections at days 0, 3, 7, 14 and 28. Reduced vaccination regimens such as the 2-1-1 have been proven to be efficient in raising protective antibody responses. Reduction in the total volume of rabies vaccine is also possible by using the intradermal route of injection, provided the vaccine is administered at several sites. The overall consequence is a progressive shift in the worldwide use of rabies vaccines from those of nervous tissue origin to the contemporary tissue culture vaccines.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Krebs JW, Strine TW, Smith JS, et al. Rabies surveillance in the Unites States during 1995. J Am Vet Med Assoc 1996; 209: 2031–43
Epidemiological surveillance of rabies in the Americas. IN-PPAZ (Pan American Institute of Food Protection and Zoonoses), 1995
Rabies Bulletin Europe - information, surveillance, research. Tübingen: WHO Collaborating Centre for Rabies Surveillance and Research
WHO Report of the 3rd International Symposium on Rabies in Asia; 1996 Sep 11–15: Wuhan. WHO/EMC/ZOO/96.8
WHO Survey of Rabies. No. 30, 1994. WHO/EMC/ZOO/96.3
Galtier V. Les injections de virus rabique dans le torrent circulatoire ne provoquent pas l’éclosion de la rage et semblent conférer l’immunité. La rage peut être transmise par l’ingestion de la matière rabique. C R Acad Sci 1881; 93: 284–5
Pasteur L. Méthode pour prévenir la rage après morsure. C R Acad Sci 1885; 33: 177–82
Fermi C. Über die Immunizierung gegen Wutkrankheit. Z Hyg Infekt 1907; 58: 233–77
Semple D. On the nature of rabies and antirabies treatment. BMJ 1919; 2: 333
Fuenzalida E, Palacios R. Rabies vaccine prepared from brains of infected suckling mice. Bol Inst Bacteriol [Chile] 1955; 8: 3–10
Koprowski H, Cox HR. Studies on chick embryo adapted rabies virus: I. Culture characteristics and pathogenicity. J Immunol 1948; 60: 533–54
Powell HM, Culbertson CG. Cultivation of fixed rabies virus in embryonated duck egg. Public Health Rep 1950; 65: 400–1
Schell KR, Fürst M, Haberstich HU, et al. A highly purified and concentrated duck embryo rabies vaccine: a preliminary report. J Biol Stand 1980; 8: 97–106
Glück R, Keller H, Mischler R, et al. New aspects concerning the immunogenicity of rabies vaccines produced in animal brains (duck embryo). In: Kuwert E, Mérieux C, Koprowski H, et al., editors. Rabies in the tropics. Berlin: Springer-Verlag, 1985: 181–8
Kissling RE. Growth of rabies virus in non nervous tissue culture. Proc Soc Exp Biol Med 1958; 98: 223–5
Wiktor TJ, Fernandes MV, Koprowski H. Cultivation of rabies virus in human diploid cell strain in WI-38. J Immunol 1964; 93: 353–60
Kissling RE, Reese DR. Antirabies vaccine of tissue culture origin. J Immunol 1965; 91: 363–8
Wiktor TJ, Koprowski H. Successful immunization of primates with rabies vaccine prepared in human diploid cell strain WI38. Proc Soc Exp Biol Med 1965; 1187: 1069–73
Fenje P. A rabies vaccine from hamster kidney tissue cultures: preparation and evaluation in animals. Can J Microbiol 1960; 6: 605–9
Selimov M, Aksenova T, Klyueva E, et al. Evaluation of the inactivated tissue culture rabies vaccine from the Vnukovo-32 strain: results of its industrial production and field use for post-exposure immunization in man. Dev Biol Stand 1978; 40: 57–62
Lin FT, Zeng F, Lu L, et al. The primary hamster kidney cell rabies vaccine: adaptation of viral strain, production of vaccine, and pre and postexposure treatment. J Infect Dis 1983; 147: 467–73
Tang Q, Zhao X, Dou Z. Control and prevention of rabies in China [abstract no. 6.03]. International Rabies Meeting; 1997 Mar 13–14: Paris
Wiktor TJ, Sokol F, Kuwert E, et al. Immunogenicity of concentrated and purified rabies vaccine of tissue culture origin. Proc Soc Exp Biol Med 1969; 131: 799–805
Wiktor TJ, Plotkin S, Grella DW. Human cell culture rabies vaccine. JAMA 1973; 224: 1170–1
Bahmanyar M, Fayaz A, Nour-Salehi S, et al. Successful protection of humans exposed to rabies infection: post exposure treatment with the new human diploid cell rabies vaccine and antirabies serum. JAMA 1976; 236: 2751–4
Van Wezel AL. Growth of cell strains and primary cells on microcarriers in homogenous cultures. Nature 1967; 216: 64
Yasumura Y, Kawakita Y. Studies on SV40 in tissue culture -preliminary step for cancer research in vitro [in Japanese]. Nihon rinsho 1967; 21: 1201–15
Montagnon BJ. Polio and rabies vaccines produced in continuous cell lines: a reality for VERO cell lines. Dev Biol Stand 1989; 70: 27–47
Van Steenis G, Van Wezel AL. Use of ATG-treated newborn rat for ‘in vivo’ tumorigenicity testing of cell substrates. Dev Biol Stand 1982; 50: 37–46
Montagnon BJ, Fanget B. Purified vero cell vaccine for humans. In: Meslin FX, Kaplan MM, Koprowski H, editors. Laboratory techniques in rabies. Geneva: WHO 1996: 285–9
Fournier P, Montagnon B, Vincent-Falquet JC, et al. A new vaccine produced from rabies virus cultivated in VERO cells. In: Vodopija I, Nicholson KG, Smerdel S, et al., editors. Improvements in rabies post-exposure treatments. Zagreb: Institute of Public Health, 1985: 115–21
Montagnon BJ, Fournier P, Vincent-Falquet JC. Un nouveau vaccin antirabique à usage humain: rapport préliminaire. In: Kuwert E, Mérieux C, Koprowski H, editors. Rabies in the tropics. Berlin: Springer-Verlag, 1985: 138–43
Ajian N, Pilet C. Comparative study of the safety and protective value in pre-exposure use, of rabies vaccine cultivated on human diploid cells (HDCV) and of the new vaccine grown on VERO cells. Vaccine 1989; 7: 125–8
Suntharasamai P, Warrel MJ, Warrel DA, et al. New purified VERO-cell vaccine prevents rabies in patients bitten by rabid animals. Lancet 1986; 2: 129–31
Kondo A, Takashima Y, Suzuki M. Inactivated rabies vaccine of chick embryo cell culture origin. Symp Series Immunobiol Stand 1974; 21: 182–9
Koprowski H, Cox HR. Studies on chick embryo adapted rabies virus: I. Culture characteristics and pathogenicity. J Immunol 1948; 60: 533–54
Barth R, Franke V. Purified chick-embryo cell vaccine for humans. In: Meslin FX, Kaplan MM, Koprowski H, editors. Laboratory techniques in rabies. Geneva: WHO, 1996: 290–5
Bijok U, Barth R, Grushhkau H, et al. Clinical trials in healthy volunteers with the new purified chick embryo cell rabies vaccine for man. In: Kuwert E, Mérieux C, Koprowski H, editors. Rabies in the tropics. Berlin: Springer-Verlag, 1985: 125–32
Barth R, Gruschkau H, Bijok U, et al. A new inactivated tissue-culture rabies vaccine for use in man: evaluation of PCEC vaccine by laboratory test. J Biol Stand 1984; 12: 29–46
Arai YT, Ogata T, Oya A. Studies on Japanese-produced chick embryo cell culture rabies vaccines. Am J Trop Med 1991; 44: 131–4
Berlin BS, Mitchell JR, Burgoyne GH, et al. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine: results of initial clinical studies of preexposure vaccination. JAMA 1982; 247: 1726–8
Burgoyne GH, Kajiya KD, Brown DW, et al. Rhesus diploid rabies vaccine (adsorbed): a new rabies vaccine using FRhL-2 cells. J Infect Dis 1985; 152: 204–10
Remlinger P. Pasteur et la rage de laboratoire. Bull Acad Natl Med 1935; 113: 13–27
WHO Rabies Expert Committee (Technical Report Series, No. 824). 8th Report. Geneva: WHO, 1992
Vodopija I, Sureau P, Lafon M. An evaluation of second generation tissue culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination and an abbreviated 2-1-1 post-exposure schedule. Vaccine 1986; 4: 245–8
Wasi C, Chaiprasithikul P, Auewarakul P, et al. The abbreviated 2-1-1 schedule of purified chick embryo cell rabies vaccination for rabies postexposure treatment. Vaccine 1993; 24: 461–6
Suntharasamai P, Chaiprasithikul P, Wasi C, et al. A simplified and economical intradermal regimen of purified chick embryo cell rabies vaccine for post-exposure prophylaxis. Vaccine 1994; 12: 508–12
WHO Recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies. 1997. WHO/EMC/ZOO.96.6
Cox JH, Schneider LG. Prophylactic immunization of humans against rabies by intradermal inoculation of human diploid cell culture vaccine. J Clin Microbiol 1976; 3: 96–101
Habel K, Koprowski H. Laboratory data supporting the clinical trial of antirabies serum in persons bitten by a rabid wolf. Bull World Health Organ 1955; 13: 773–9
Baltazard M, Bahmanyar M. Essai pratique du sérum antirabique chez les mordus par loups enragés. Bull Organ Mondiale Santior 1955; 13: 747–72
Cho HC, Lawson KF. Protection of dogs against death from experimental rabies by post exposure administration of rabies vaccine and hyperimmune globulin (human). Can J Vet Res 1989; 53: 434–7
Baer GM, Cleary WF. A model in mice for the pathogenesis and treatment of rabies. J Infect Dis 1972; 125: 520–7
Crick J, Brown F. Small immunizing subunits in rabies virus. In: Barry RD, Mahy BWJ, editors. The biologogy of large RNA viruses. New York: Academic Press, 1970: 133–40
Atanasiu P, Tsiang H, Perrin P, et al. Extraction d’un antigène soluble (glycoprotéine) par le Triton X-100 à partir d’un vaccin antirabique de culture tissulaire de premier explant: résultats d’immunisation et pouvoir protecteur. Ann Microbiol (Institut Pasteur) 1974; 125B: 539–57
Cox JH, Dietzschold B, Schneider LG. Rabies virus glycoprotein: II. Biological and serological characterization. Infect Immun 1977; 30: 572–7
Dietzschold B, Wiktor TJ, Wunner WH, et al. Chemical and immunological analysis of the rabies soluble glycoprotein. Virology 1983; 124: 330–7
Wojczyk B, Shakin-Eshlman SH, Doms RW, et al. Stable secretion of a soluble, oligomeric form of rabies virus glycoprotein: influence of N-glycan processing on secretion. Biochem 1995; 34: 2599–609
Reagan KJ, Wunner WH, Wiktor H, et al. Anti-idiotype antibodies induces neutralizing antibodies to rabies virus glycoprotein. J Virol 1983; 48: 660–6
Perrin P, Thibodeau L, Sureau P. Rabies immunosomes (subunit vaccine) structure and immunogenicity. Pre- and post-exposure studies. Vaccine 1985; 3: 325–32
Fekadu M, Shaddock JH, Ekström J, et al. An immune stimulating complex (ISCOM) subunit rabies vaccine protects dogs and mice against street rabies challenge. Vaccine 1992; 10: 192–7
Ertl HCJ, Varga I, Xiang ZQ, et al. Poly (DL-lactide-co-glycolide) microspheres as carriers for peptide vaccines. Vaccine 1996; 14: 879–85
Anilionis A, Wunner WH, Curtis PJ. Structure of the glycoprotein gene in rabies virus. Nature 1981; 294: 275–8
Kieny MP, Lathe R, Drillien R, et al. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 1984; 312: 163–6
Wiktor TJ, MacFarlan RT, Reagan K, et al. Protection from rabies by a vaccinia rabies recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci USA 1984; 81: 7194–8
Yelverton E, Norton S, Obijeski JF, et al. Rabies virus glycoprotein analogs; biosynthesis in Escherichia coli. Science 1983; 219: 614–20
Lathe R, Kieny MP, Schmitt D, et al. M13 bacteriophage vectors for the expression of proteins in Escherichia coli: the rabies glycoprotein. J Mol Appl Genet 1984; 2: 331–42
Rupprecht CE, Kieny MP. Development of a vaccinia-rabies glycoprotein recombinant vaccine. In: Campbell JB, Charlton KM, editors. Rabies. Boston: Kluwer Academic Press, 1988: 335–64
Préhaud C, Takehara K, Flamand A, et al. Immunogenic and protective properties of rabies virus glycoprotein expressed by baculovirus vectors. Virology 1989; 173: 390–9
Klepfer SR, Debouck C, Uffelman J, et al. Characterization of rabies glycoprotein expressed in yeast. Arch Virol 1993; 128: 269–86
Prevec L, Campbell JB, Chistie BS, et al. A recombinant human adenovirus vaccine against rabies. J Infect Dis 1990; 161: 27–30
Cadoz M, Strady A, Meignier B, et al. Immunization with canarypox virus expressing rabies glycoprotein. Lancet 1992; 339: 1429–32
Taylor J, Tataglia J, Riviere M, et al. Application of canarypox (ALVAC) vectors in human and veterinary vaccination. Dev Biol Stand 1994; 82: 131–5
Xiang ZQ, Spitalnik SL, Tran M, et al. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology 1994; 199: 132–40
Xiang ZQ, Spitalnik SL, Cheng J, et al. Immune response to nucleic acid vaccines to rabies virus. Virology 1995; 209: 569–79
Ertl HCJ, Xiang ZQ. Genetic immunization. Life Sciences 1996; 9: 1–9
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tsiang, H. Rabies Vaccines. BioDrugs 10, 317–328 (1998). https://doi.org/10.2165/00063030-199810040-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00063030-199810040-00006